Galanin protects against intracellular amyloid toxicity in human primary neurons

Journal of Alzheimer's Disease

Volumn 19, Issue 2, 2010, Pages 529-544

  Cui, Jia ^a   Chen, Qiuyue ^a   Yue, Xiaojing ^b   Jiang, Xuejun ^c   Gao, George F ^c   Yu, Long Chuan ^a   Zhang, Yan ^a  

^a PEKING UNIVERSITY   (China)

^b MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

^c INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

Alzheimer's disease; Galanin; Human primary neurons; Neuronal loss

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ETOPOSIDE; GALANIN; GALANIN RECEPTOR 2; GALANIN[2-11]; GALANTIDE; HYDROGEN PEROXIDE; PROTEIN BAX; STAUROSPORINE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NERVE CELL; NERVE CELL CULTURE; NEUROPROTECTION; NEUROTOXICITY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; SERUM;

EID: 77049107344     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1246     Document Type: Article

References (65)

1. Price DL, Sisodia SS, Gandy SE (1995) Amyloid beta amyloidosis in Alzheimer's disease. Curr Opin Neurol 8, 268-274.
2. Cuello AC (2005) Intracellular and extracellular Abeta, a tale of two neuropathologies. Brain Pathol 15, 66-71.
3. Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM (2006) A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol 168, 184-194.
4. Busciglio J, Pelsman A,Wong C, Pigino G, Yuan M, Mori H, Yankner BA (2002) Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33, 677-688.
5. Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK (2002) Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161, 1869-1879.
6. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156, 15-20.
7. D'Andrea MR, Nagele RG, Gumula NA, Reiser PA, Polkovitch DA, Hertzog BM, Andrade-Gordon P (2002) Lipofuscin and Abeta42 exhibit distinct distribution patterns in normal and Alzheimer's disease brains. Neurosci Lett 323, 45-49.
8. D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH (2001) Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 38, 120-134.
9. Tabira T, Chui DH, Kuroda S (2002) Significance of intracellular Abeta42 accumulation in Alzheimer's disease. Front Biosci 7, a44-49.
10. Chui DH, Tanahashi H, Ozawa K, Ikeda S, Checler F, Ueda O, Suzuki H, Araki W, Inoue H, Shirotani K, Takahashi K, Gallyas F, Tabira T (1999) Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med 5, 560-564.
11. Wang HY, D'Andrea MR, Nagele RG (2002) Cerebellar diffuse amyloid plaques are derived from dendritic Abeta42 accumulations in Purkinje cells. Neurobiol Aging 23, 213-223.
12. Van Broeck B, Vanhoutte G, Pirici D, Van Dam D, Wils H, Cuijt I, Vennekens K, Zabielski M, Michalik A, Theuns J, De Deyn PP, Van der Linden A, Van Broeckhoven C, Kumar- Singh S (2008) Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease. Neurobiol Aging 29, 241-252.
13. Cruz JC, Kim D, Moy LY, Dobbin MM, Sun X, Bronson RT, Tsai LH (2006) p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. J Neurosci 26, 10536-10541.
14. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26, 10129-10140.
15. Knobloch M, Konietzko U, Krebs DC, Nitsch RM (2007) Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging 28, 1297-1306
16. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421.
17. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM (2005) Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45, 675-688.
18. Zhang Y, McLaughlin R, Goodyer C, LeBlanc A (2002) Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol 156, 519-529.
19. Tatemoto K, Rokaeus A, Jornvall H, McDonald TJ, Mutt V (1983) Galanin - a novel biologically active peptide from porcine intestine. FEBS Lett 164, 124-128.
20. Counts SE, Perez SE, Ginsberg SD, De Lacalle S, Mufson EJ (2003) Galanin in Alzheimer disease. Mol Interv 3, 137-156.
21. Wilcock GK, Esiri MM, Bowen DM, Smith CC (1982) Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 57, 407-417.
22. Hokfelt T (2005) Galanin and its receptors: introduction to the Third International Symposium, San Diego, California, USA, 21-22 October 2004. Neuropeptides 39, 125-142.
23. BealMF, MacGarvey U, Swartz KJ (1990) Galanin immunoreactivity is increased in the nucleus basalis of Meynert in Alzheimer's disease. Ann Neurol 28, 157-161.
24. Diez M, Koistinaho J, Kahn K, Games D, Hokfelt T (2000) Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F beta-amyloid precursor protein-initial observations. Neuroscience 100, 259-286.
25. Diez M, Danner S, Frey P, Sommer B, Staufenbiel M,Wiederhold KH, Hokfelt T (2003) Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing beta-amyloid precursor protein (APP) with the Swedish double mutation (APP23). Neurobiol Dis 14, 579-594.
26. Rustay NR, Wrenn CC, Kinney JW, Holmes A, Bailey KR, Sullivan TL, Harris AP, Long KC, Saavedra MC, Starosta G, Innerfield CE, Yang RJ, Dreiling JL, Crawley JN (2005) Galanin impairs performance on learning and memory tasks: findings from galanin transgenic and GAL-R1 knockout mice. Neuropeptides 39, 239-243.
27. Badie-Mahdavi H, Behrens MM, Rebek J, Bartfai T (2005) Effect of galnon on induction of long-term potentiation in dentate gyrus of C57BL/6 mice. Neuropeptides 39, 249-251.
28. Dutar P, Lamour Y, Nicoll RA (1989) Galanin blocks the slow cholinergic EPSP in CA1 pyramidal neurons from ventral hippocampus. Eur J Pharmacol 164, 355-360.
29. Mufson EJ, Counts SE, Perez SE, Binder L (2005) Galanin plasticity in the cholinergic basal forebrain in Alzheimer's disease and transgenic mice. Neuropeptides 39, 233-237.
30. Counts SE, Chen EY, Che S, Ikonomovic MD, Wuu J, Ginsberg SD, Dekosky ST, Mufson EJ (2006) Galanin fiber hypertrophy within the cholinergic nucleus basalis during the progression of Alzheimer's disease. Dement Geriatr Cogn Disord 21, 205-214.
31. Holmes FE, Mahoney SA,WynickD(2005) Use of genetically engineered transgenic mice to investigate the role of galanin in the peripheral nervous system after injury. Neuropeptides 39, 191-199.
32. Roucou X, Giannopoulos PN, ZhangY, Jodoin J, Goodyer CG, LeBlanc A (2005) Cellular prion protein inhibits proapoptotic Bax conformational change in human neurons and in breast carcinoma MCF-7 cells. Cell Death Differ 12, 783-795.
33. LeBlanc A (1995) Increased production of 4 kDa amyloid beta peptide in serum deprived human primary neuron cultures: possible involvement of apoptosis. J Neurosci 15, 7837-7846.
34. Soond SM, Carroll C, Townsend PA, Sayan E, Melino G, Behrmann I, Knight RA, Latchman DS, Stephanou A (2007) STAT1 regulates p73-mediated Bax gene expression. FEBS Lett 581, 1217-1226.
35. Bacon A, Kerr NC, Holmes FE, Gaston K, Wynick D (2007) Characterization of an enhancer region of the galanin gene that directs expression to the dorsal root ganglion and confers responsiveness to axotomy. J Neurosci 27, 6573-6580.
36. Holmes PV, Crawley JN(1996) Olfactory bulbectomy increases prepro-galanin mRNA levels in the rat locus coeruleus. Brain Res Mol Brain Res 36, 184-188.
37. Ma W, Bisby MA (1997) Differential expression of galanin immunoreactivities in the primary sensory neurons following partial and complete sciatic nerve injuries. Neuroscience 79, 1183-1195.
38. Villar MJ, Meister B, Hokfelt T (1994) Reorganization of neural peptidergic systems in the median eminence after hypophysectomy. J Neurosci 14, 5996-6012.
39. Kashiba H, Ueda Y, Senba E (1997) Systemic capsaicin in the adult rat differentially affects gene expression for neuropeptides and neurotrophin receptors in primary sensory neurons. Neuroscience 76, 299-312.
40. Xu XJ, Farkas-Szallasi T, Lundberg JM, Hokfelt T, Wiesenfeld-Hallin Z, Szallasi A (1997) Effects of the capsaicin analogue resiniferatoxin on spinal nociceptive mechanisms in the rat: behavioral, electrophysiological and in situ hybridization studies. Brain Res 752, 52-60.
41. ZhangY, Goodyer C, LeBlancA(2000) Selective and protracted apoptosis in human primary neurons microinjected with active caspase-3, -6, -7, and -8. J Neurosci 20, 8384-8389.
42. McGinnis KM, Gnegy ME, Wang KK (1999) Endogenous bax translocation in SH-SY5Y human neuroblastoma cells and cerebellar granule neurons undergoing apoptosis. J Neurochem 72, 1899-1906.
43. Chetsawang B, Putthaprasart C, Phansuwan-Pujito P, Govitrapong P (2006) Melatonin protects against hydrogen peroxide-induced cell death signaling in SH-SY5Y cultured cells: involvement of nuclear factor kappa B, Bax and Bcl-2. J Pineal Res 41, 116-123.
44. Thomadaki H, Talieri M, Scorilas A (2006) Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12,BAX,CASPASE-9 and FAS. Biol Chem 387, 1081-1086.
45. Dohm CP, Siedenberg S, Liman J, Esposito A, Wouters FS, Reed JC, Bahr M, Kermer P, Oh YJ, Uhland-Smith A, Kim JE, O'Malley KL (2006) Bax inhibitor-1 protects neurons from oxygen-glucose deprivation regions outside of the Bcl-2 homology domains, BH1 and BH2 protect a dopaminergic neuronal cell line from staurosporine-induced cell death. J Mol Neurosci 29, 1-8.
46. Aoki M, Morishita R, Matsushita H, Nakano N, Hayashi S, Tomita N, Yamamoto K, Moriguchi A, Higaki J, Ogihara T (1997) Serum deprivation-induced apoptosis accompanied by up-regulation of p53 and bax in human aortic vascular smooth muscle cells. Heart Vessels Suppl 12, 71-75.
47. Song K, Kim YS, Moon SK, Ko CN, Cho KH, Bae HS, Lee KS (2001) Effects of uwhangchungsimwon on cell viability, proliferation, and gene expression of human neuronal cell line IMR32. Am J Chin Med 29, 445-458.
48. Jacoby AS, Hort YJ, Constantinescu G, Shine J, Iismaa TP (2002) Critical role for GALR1 galanin receptor in galanin regulation of neuroendocrine function and seizure activity. Brain Res Mol Brain Res 107, 195-200.
49. Frank GK, Kaye WH, Sahu A, Fernstrom J, McConaha C (2001) Could reduced cerebrospinal fluid (csf) galanin contribute to restricted eating in anorexia nervosa? Neuropsychopharmacology 24, 706-709.
50. Grenback E, Hulting AL, Bucht E (2005) Galanin in human plasma. Neuropeptides 39, 337-340.
51. Elliott-Hunt CR, Marsh B, Bacon A, Pope R, Vanderplank P, Wynick D (2004) Galanin acts as a neuroprotective factor to the hippocampus. Proc Natl Acad Sci U S A 101, 5105-5110.
52. Elliott-Hunt CR, Pope RJ, Vanderplank P, Wynick D (2007) Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage. J Neurochem 100, 780-789.
53. Mazarati A, Lu X, Shinmei S, Badie-Mahdavi H, Bartfai T (2004) Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GalR1) knockout mice. Neuroscience 128, 431-441.
54. Sarang SS, Yoshida T, Cadet R, Valeras AS, Jensen RV, Gullans SR (2002) Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays. Physiol Genomics 11, 45-52.
55. Holst JJ, Bersani M, Hvidberg A, Knigge U, Christiansen E, Madsbad S, Harling H, Kofod H (1993) On the effects of human galanin in man. Diabetologia 36, 653-657.
56. Fisone G,Wu CF, Consolo S, Nordstrom O, Brynne N, Bartfai T, Melander T, Hokfelt T (1987) Galanin inhibits acetylcholine release in the ventral hippocampus of the rat: histochemical, autoradiographic, in vivo, and in vitro studies. Proc Natl Acad Sci U S A 84, 7339-7343.
57. Fathi Z, Battaglino PM, Iben LG, Li H, Baker E, Zhang D, McGovern R, Mahle CD, Sutherland GR, Iismaa TP, Dickinson KE, Zimanyi IA (1998) Molecular characterization, pharmacological properties and chromosomal localization of the human GALR2 galanin receptor. Brain Res Mol Brain Res 58, 156-169.
58. Borowsky B, Walker MW, Huang LY, Jones KA, Smith KE, Bard J, Branchek TA, Gerald C (1998) Cloning and characterization of the human galanin GALR2 receptor. Peptides 19, 1771-1781.
59. Priller J, Haas CA, Reddington M, Kreutzberg GW (1998) Cultured astrocytes express functional receptors for galanin. Glia 24, 323-328.
60. Pirondi S,Kuteeva E, Giardino L, Ferraro L, Antonelli T, Bartfai T, Ogren SO, Hokfelt T, Calza L (2005) Behavioral and neurochemical studies on brain aging in galanin overexpressing mice. Neuropeptides 39, 305-312.
61. Hobson SA, Holmes FE, Kerr NC, Pope RJ,Wynick D (2006) Mice deficient for galanin receptor 2 have decreased neurite outgrowth from adult sensory neurons and impaired pain-like behaviour. J Neurochem 99, 1000-1010.
62. Lu X, Sharkey L, Bartfai T (2007) The brain galanin receptors: targets for novel antidepressant drugs. CNS Neurol Disord Drug Targets 6, 183-192.
63. Ogren SO, Kuteeva E, Hokfelt T,Kehr J (2006) Galanin receptor antagonists: a potential novel pharmacological treatment for mood disorders. CNS Drugs 20, 633-654.
64. Barr AM, Kinney JW, Hill MN, Lu X, Biros S, Rebek J, Jr., Bartfai T (2006)Anovel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests. Neurosci Lett 405, 111-115.
65. Konkel MJ, Lagu B, Boteju LW, Jimenez H, Noble S, Walker MW, Chandrasena G, Blackburn TP, Nikam SS, Wright JL, Kornberg BE, Gregory T, Pugsley TA, Akunne H, Zoski K, Wise LD (2006) 3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists. J Med Chem 49, 3757-3758.